poisar

Filings · News reference

NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results

Fiscal.ai

NextCure reported its third quarter 2026 financial results and provided an update on its pending merger with Avere Therapeutics, including the effectiveness of its S-4 registration statement.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — NextCure, Inc. (NXTC)

    Filed: 2026-10-30 AccNo: 0001104659-26-120405 Size: 161 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers